Phaseline

Companies › CellSeed

CellSeed: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Immunology; next expected readout Dec 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CLS2901C
Human allogeneic chondrocyte sheets for cartilage repair
–Phase 3Osteoarthritis of the KneeDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06549686CLS2901CPhase 3Osteoarthritis of the KneeImmunologyDec 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Lipogems International PainTEQ R-Bio Wooshin Labottach Xentria

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.